PHENOTYPIC MARKERS FOR CELL THERAPY AND RELATED METHODS
Provided are methods, compositions and articles of manufacture for use in cell therapy involving the administration of one or more doses of a therapeutic T cell composition, and methods, compositionsand articles of manufacture for use in the same. The cells of the T cell composition express recombin...
Gespeichert in:
Hauptverfasser: | , , , , , , , |
---|---|
Format: | Patent |
Sprache: | chi ; eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Provided are methods, compositions and articles of manufacture for use in cell therapy involving the administration of one or more doses of a therapeutic T cell composition, and methods, compositionsand articles of manufacture for use in the same. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the embodiments of the present disclosure, including the dose of cells or units of cells administered and/or the phenotype of administered cells, provide various advantages, such as consistent dosing, lower risk of toxicity and/or increased response in subjects administered the T cell compositions.
提供了用于在细胞疗法中使用的方法、组合物和制品,所述细胞疗法涉及给予一个或多个剂量的治疗性T细胞组合物;以及用于在所述细胞疗法中使用的方法、组合物和制品。所述T细胞组合物的细胞表达重组受体或其他转基因受体,所述重组受体如为嵌合受体,例如嵌合抗原受体(CAR),所述其他转基因受体如T细胞受体(TCR)。本公开文本的实施方案的特征(包括所给予细胞的剂量或细胞的单位和/或所给予细胞的表型)提供了各种优点,如被给予所述T细胞组合物的受试者的一致给药、较低毒性风险和/或增加的反应。 |
---|